| Clinical characteristics | Neurological symptoms group (n = 27) | Non-neural symptoms group (n = 23) | χ2 | P |
| Gender |
|
|
|
|
| Male | 17 | 18 | 1.384 | 0.239 |
| Female | 10 | 5 |
|
|
| Age(y) |
|
|
|
|
| ≥60 | 13 | 15 | 1.469 | 0.266 |
| <60 | 14 | 8 |
|
|
| Primary tumor |
|
|
|
|
| Lung cancer | 18 | 17 |
|
|
| Breast cancer | 4 | 2 |
|
|
| Colorectal cancer | 2 | 2 | 5.410 | 0.610 |
| Pleural mesothelioma | 1 | 0 |
|
|
| NHL | 1 | 0 |
|
|
| Ureteral cancer | 0 | 1 |
|
|
| Renal Pelvis Cancer | 1 | 0 |
|
|
| Number of brain metastases |
|
|
|
|
| ≥3 | 15 | 12 | 0.057 | 0.811 |
| <3 | 12 | 11 |
|
|
| Maximum diameter of brain metastases (cm) |
|
|
|
|
| ≥3 | 9 | 6 | 0.311 | 0.577 |
| <3 | 18 | 17 |
|
|
| Transfer to other parts |
|
|
|
|
| Yes | 21 | 12 | 3.628 | 0.057 |
| No | 6 | 11 |
|
|
| Previous history of chemotherapy |
|
|
|
|
| Yes | 22 | 17 | 0.415 | 0.520 |
| No | 5 | 6 |
|
|
| Previous molecular targeted therapy |
|
|
|
|
| Yes | 19 | 14 | 0.500 | 0.480 |
| No | 8 | 9 |
|
|
| Previous intracranial pressure reduction treatment |
|
|
|
|
| Yes | 17 | 12 | 0.593 | 0.441 |
| No | 10 | 11 |
|
|